LCTX (Lineage Cell Therapeutics) Cyclically Adjusted Book per Share: $0.88 (As of Mar. 2026)


LCTX Lineage Cell Therapeutics Inc LCTX
79 GF Score
Price $1.31
GF Value $1.33
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Lineage Cell Therapeutics Cyclically Adjusted Book per Share?

Lineage Cell Therapeutics LCTX 79 Cyclically Adjusted Book per Share is $0.88 as of Mar. 2026. GuruFocus rates LCTX with a GF Score™ of 79/100 and a GF Value™ of $1.33 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Lineage Cell Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $0.216. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.88 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Lineage Cell Therapeutics's average Cyclically Adjusted Book Growth Rate was 2.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 2.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 3.80% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 12.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Lineage Cell Therapeutics was 41.30% per year. The lowest was -40.70% per year. And the median was 5.50% per year.

As of today (2026-07-01), Lineage Cell Therapeutics's current stock price is $1.31. Lineage Cell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $0.88. Lineage Cell Therapeutics's Cyclically Adjusted PB Ratio of today is 1.49.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lineage Cell Therapeutics was 14.12. The lowest was 0.48. And the median was 1.82.


Lineage Cell Therapeutics  (AMEX:LCTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Lineage Cell Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.31/0.88
=1.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lineage Cell Therapeutics was 14.12. The lowest was 0.48. And the median was 1.82.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Lineage Cell Therapeutics Cyclically Adjusted Book per Share Related Terms


Lineage Cell Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Lineage Cell Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lineage Cell Therapeutics Cyclically Adjusted Book per Share Chart

Lineage Cell Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.80 0.82 0.85 0.86

Lineage Cell Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.87 0.87 0.86 0.88

LCTX vs NWBO, ABEO, VRXA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Lineage Cell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lineage Cell Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's Cyclically Adjusted PB Ratio falls into.


LCTX
79GF Score
Lineage Cell Therapeutics Inc LCTX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lineage Cell Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lineage Cell Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.216/330.2130*330.2130
=0.216

Current CPI (Mar. 2026) = 330.2130.

Lineage Cell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.843 241.018 1.155
201609 1.162 241.428 1.589
201612 1.147 241.432 1.569
201703 1.690 243.801 2.289
201706 1.588 244.955 2.141
201709 1.712 246.819 2.290
201712 1.282 246.524 1.717
201803 0.788 249.554 1.043
201806 0.796 251.989 1.043
201809 1.349 252.439 1.765
201812 0.738 251.233 0.970
201903 1.090 254.202 1.416
201906 0.891 256.143 1.149
201909 0.782 256.759 1.006
201912 0.754 256.974 0.969
202003 0.711 258.115 0.910
202006 0.664 257.797 0.851
202009 0.608 260.280 0.771
202012 0.628 260.474 0.796
202103 0.726 264.877 0.905
202106 0.747 271.696 0.908
202109 0.717 274.310 0.863
202112 0.544 278.802 0.644
202203 0.510 287.504 0.586
202206 0.488 296.311 0.544
202209 0.465 296.808 0.517
202212 0.431 296.797 0.480
202303 0.414 301.836 0.453
202306 0.417 305.109 0.451
202309 0.389 307.789 0.417
202312 0.362 306.746 0.390
202403 0.384 312.332 0.406
202406 0.362 314.175 0.380
202409 0.350 315.301 0.367
202412 0.356 315.605 0.372
202503 0.346 319.799 0.357
202506 0.212 322.561 0.217
202509 0.096 324.800 0.098
202512 0.183 324.054 0.186
202603 0.216 330.213 0.216

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $0.88 mean?
Lineage Cell Therapeutics (LCTX) has a Cyclically Adjusted Book per Share of $0.88 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Lineage Cell Therapeutics and its competitors.
Is Lineage Cell Therapeutics' Cyclically Adjusted Book per Share too high?
Lineage Cell Therapeutics' current Cyclically Adjusted Book per Share is $0.88. Overall, Lineage Cell Therapeutics has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' Cyclically Adjusted Book per Share compare to NWBO and ABEO?
Lineage Cell Therapeutics' Cyclically Adjusted Book per Share of $0.88 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Lineage Cell Therapeutics and its competitors. Lineage Cell Therapeutics's current Cyclically Adjusted Book per Share is $0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Fairly Valued. The stock's GF Value™ is $1.33, compared to a current price of $1.31 — trading 1.5% below its estimated fair value. The current Cyclically Adjusted Book per Share is $0.88. Lineage Cell Therapeutics' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current Cyclically Adjusted Book per Share is $0.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?

Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued. The current stock price of $1.31 is trading 1.5% below its estimated GF Value™ of $1.33. GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.

Key valuation signals for LCTX:

  • Cyclically Adjusted Book per Share: $0.88
  • GF Value™: $1.33 vs. price of $1.31 (1.5% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lineage Cell Therapeutics Business Description

Other Exchanges LCTX:IsraelBT3:Germany
Address 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
79GF Score

Get the complete analysis for LCTX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.31
Price
$1.33
GF Value